A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.79% higher to $477.90 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 ...

This investor is excited about the transformational potential of one growth stock that he's been eyeing up for his portfolio.

Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $29.9 billion by 2032, ...

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day. This move outpaced the S&P 500's daily gain of 0.13%. At the same time, the Dow ...

Earlier this year, Eli Lilly and Co. opened a new research and development center in Fort Point, adjacent to the Seaport.